Eton Pharmaceuticals
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| approved | ×0.70 | 3 |
Strategy profile
Based on 3 disclosed transactions, Eton Pharmaceuticals concentrates its licensing activity in Metabolic, RareDisease. Eton Pharmaceuticals pays a 0.70x discount to market median. Their most common deal structure is Acquisition, with an average disclosed value of $14M. Most recent activity: 2024.
Pipeline coverage & gaps
Eton Pharmaceuticals has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| AcquisitionPrimary | 2 | $12M | $20M |
| License | 1 | $2M | $4M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2024 | Increlex | Ipsen S.A. | severe primary IGF-1 deficiency | approved | $23M | $35M |
| 2024 | PKU GOLIKE | Relief Therapeutics | phenylketonuria (PKU) | approved | $2M | $4M |
| 2024 | GOLIKE | Relief Therapeutics Holding AG | Phenylketonuria (PKU) | approved | $2M | $4M |
How this is computed
For each Eton Pharmaceuticals deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.062, clamped to [0.7, 1.5].